Protalix BioTherapeutics Inc Sustainability Reports
Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company's commercial portfolio includes Elelyso for Gaucher disease and Elfabrio for Fabry disease.
Sector: Manufacturing
Country: Israel
Exchange: NYSE American
LEI: 549300SDVB3GP4XDFM60
FIGI: BBG001SBVMW4
4 reports from 2007 to 2023
